Background
==========

In the brain, fast inhibitory electrical signaling is mediated primarily by the family of γ-aminobutyric acid (GABA)~A~ receptors, making them important modulators of all neural processing. Harrison and Simmonds ([@B82]) provided the first clear evidence that neuroactive steroids act at specific neurotransmitter receptors, investigating the ability of alphaxalone (3α-hydroxy-5α-pregnane l l,20-dione) to potentiate responses at GABA~A~ receptors induced by muscimol in cortical slices. Within 2 years, a progesterone metabolite (3α-hydroxy-5α-pregnan-20-one, 3α,5α-THP, allopregnanolone) and a deoxycorticosterone metabolite (3α,21-dihydroxy-5α-pregnan-20-one, 3α,5α-THDOC, tetrahydrodeoxycorticosterone) were shown to be positive modulators of GABA~A~ receptors (Majewska et al., [@B125]). That same year, publications showed that ethanol has direct action at GABA~A~ receptors (Allan and Harris, [@B3]; Suzdak et al., [@B191]). Thus, the GABA~A~ receptor complex was identified as a membrane-bound target providing a pharmacological basis for shared sensitivity between neurosteroids and ethanol. The common behavioral effects of ethanol and neuroactive steroids were compared directly using drug discrimination procedures (Ator et al., [@B6]). The *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor complex, a membrane-bound ionophore important for excitatory glutamate neurotransmission, was shown to be antagonized by low concentrations of ethanol (Lovinger et al., [@B122]). Soon, data was showing that neurosteroids act at NMDA receptors (Wu et al., [@B210]). Thus, by the mid-1990s, the stage was set for the suggestion that neurosteroids, and physiological states that alter circulating neuroactive steroids, could affect sensitivity to ethanol (Grant et al., [@B71]).

Neuroactive Steroids Modulate Neurotransmission in an Isomeric-Dependent Manner
===============================================================================

Neuroactive steroids are produced in peripheral organs, including testes, ovaries, adrenal glands, lung, and liver, but can cross the blood--brain barrier and be metabolized in the brain. Further, neurosteroids are produced *de novo* in the brain. Whether of peripheral or central origin, all neuroactive steroids are derived from cholesterol. The transport of cholesterol to the inner mitochondrial membrane, mediated by steroidogenic acute regulatory protein (StAR), is the rate-limiting step in steroidogenesis (Stocco and Clark, [@B190]). At the inner mitochondrial membrane, the enzyme P450 side-chain cleavage transforms cholesterol to pregnenolone. Neuroactive steroids with activity at GABA~A~ receptors are metabolites of the precursor steroids deoxycorticosterone, progesterone, testosterone, and androstenedione (Figure [1](#F1){ref-type="fig"}). Transformation of these precursors, respectively, first by 5α-reductase and then by 3α-hydroxysteroid dehydrogenase (HSD) produces 3α,5α-THDOC, 3α,5α-P, and 5α-androstan-3α-ol-17-one (3α,5α-A; androsterone). Each of these steroids, in addition to the 5β-reduced pregnane steroid 3α-hydroxy-5β-pregnan-20-one (3α,5β-P, pregnanolone), positively modulates responses to GABA at GABA~A~ receptors (Puia et al., [@B156]; Park-Chung et al., [@B140]). Specifically, this means that the efficacy of GABA is increased by concentrations of steroid that do not, by themselves, activate the receptor. In contrast, muscimol and gaboxadol \[4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridin-3(-ol); THIP\] are direct agonists of GABA~A~ receptors because they open the Cl^−^ channel in the absence of GABA. The pharmacological activity of neuroactive steroids depends on their isomeric configuration, which is determined by the steroidogenic enzymes that are present. Transformation by 5β-reductase and then by 3β-HSD results in neuroactive steroids that have distinct pharmacological activity resembling neuroactive steroids to which a sulfate group has been added (Wang et al., [@B202]). Sulfation by sulfotransferase enzymes is a low-energy strategy by which the effects of neuroactive steroids on neurotransmission may be adjusted (Gibbs et al., [@B62]). Sulfated or 3β-reduced steroids negatively modulate GABA~A~ receptors (e.g., pregnanolone sulfate, epipregnanolone sulfate, androsterone sulfate, epiandrosterone sulfate). Other activity includes negative modulation (e.g., allopregnanolone sulfate, epipregnanolone sulfate) or positive modulation of NMDA receptor responses (e.g., epiallopregnanolone sulfate). Thus, sulfation may rapidly and transiently enhance excitatory neurotransmission, as suggested by Wu et al. ([@B210]). The effects of sulfated steroids on glutamate transmission are hypothesized to regulate sensory processing and memory (Valenzuela et al., [@B193]). Overall, steroidogenesis allows for modulation of excitatory and inhibitory neurotransmission related to endocrine activity that may be an important regulator of sensitivity to environmental stimuli and behavior.

![**Neurosteroids modulating GABAergic neurotransmission are produced by the precursor steroids deoxycorticosterone (3α,5α-THDOC, allotetrahydrodeoxycorticosterone), progesterone (3α,5α-P, allopregna-nolone; 3α,5β-P, pregnenolone; 3β,5α-P, epiallopregnanolone; 3β,5β-P, epipregnanolone), and testosterone (3α,5α-A, androsterone; 3α,5β-A, etiocholanolone) via the sequential actions of reductase and hydroxy-steroid dehydrogenase enzymes**. Ellipses highlight steroids known to influence sensitivity to the behavioral or endocrine effects of ethanol. Alcohol dehydrogenase and 3α-hydroxysteroid dehydrogenase require common co-factors. Sulfotransferase enzymes adding a sulfate group rapidly alter the pharmacological activity of neurosteroids. DHDOC, dihydrodeoxycortico-sterone; HSD, hydroxysteroid dehydrogenase; NADPH, nicotinamide adenine dinucleotide phosphate-oxidase; NADH, nicotinamide adenine dinucleotide; scc, side-chain cleavage; StAR, steroidogenic acute regulatory protein.](fendo-03-00010-g001){#F1}

In addition to modulating receptor responses, neurosteroids have been shown to regulate neurotransmitter release. For example, pregnenolone sulfate increased glutamate release in neonatal cerebellar synapses (Zamudio-Bulcock and Valenzuela, [@B211]) and cultured hippocampal neurons (Meyer et al., [@B127]). Likewise, an increased probability of GABA release after application of pregnanolone was observed in studies using spinal motor neurons in toad embryos (Reith and Sillar, [@B161]). Haage et al. ([@B77]) reported increased GABA release in isolated neurons from the medial preoptic area of rats after application of allopregnanolone. Thus, neurosteroids can modulate excitatory and inhibitory synaptic transmission by modulating receptor activity and neurotransmitter release. However, the efficacious actions of neuroactive steroids at GABA~A~ receptors are particularly powerful (Park-Chung et al., [@B140]).

Ethanol Affects Neuroactive Steroid and Neurosteroid Concentrations
===================================================================

The ability of neuroactive steroids to modulate sensitivity to ethanol via GABA~A~ receptors has been reviewed recently (Morrow et al., [@B133]; Biggio et al., [@B13]) and was the topic of a recent symposium on the interactions between stress and ethanol (Morrow et al., [@B132]). In addition to potentially sharing common receptor mechanisms, a major idea explored in these publications was that acute ethanol increases the release of neuroactive steroids. One mechanism involves stimulation of the hypothalamic--pituitary--adrenal (HPA) axis. Stimulation of the HPA axis results in the release of adrenocorticotropic hormone (ACTH) from the pituitary into circulation. ACTH can then stimulate the expression of StAR protein and the mitochondrial enzyme CYP11A1 (P450scc) through a second messenger pathway that involves cyclic adenosine monophosphate. As a result, ACTH promotes the production of pregnenolone from cholesterol in the adrenal cortex (Lavoie and King, [@B115]). As described, pregnenolone can be metabolized to all other neuroactive steroids depending on which steroidal enzymes are present (Figure [1](#F1){ref-type="fig"}). Also shown in Figure [1](#F1){ref-type="fig"}, hydroxysteroid dehydrogenase is a key enzyme involved in the production of neuroactive steroids, and this enzyme requires nicotinamide adenine dinucleotide phosphate (NADPH) or nicotinamide adenine dinucleotide (NADH) as a co-factor (Krause and Karavolas, [@B110]). Because the metabolism of ethanol also requires this co-factor, one possibility that requires additional investigation is that steroidogenesis could be altered in the presence of high doses of ethanol as the necessary co-factors are depleted (Crabb et al., [@B37]).

Several studies have shown that acute ethanol increases circulating neuroactive steroids (e.g., VanDoren et al., [@B194]; Porcu et al., [@B152]). As mentioned, ethanol appears to have this effect by increasing pituitary release of ACTH in conjunction with vasopressin and corticotropin releasing hormone (CRH; Lee et al., [@B118]). Adrenalectomy largely eliminates neuroactive steroids that are induced by ethanol (Porcu et al., [@B154]), indicating that ACTH stimulates adrenal production of neuroactive steroids. In rats, HPA axis activation and *de novo* synthesis of StAR protein are necessary for a threshold dose of 1.5 g/kg ethanol to increase GABAergic neuroactive steroids in plasma and cerebral cortex (Boyd et al., [@B20]). Ethanol also stimulates *de novo* steroidogenesis within the brain in principal excitatory neurons and glial cells (Chisari et al., [@B33]). In hippocampal slices from 3-week-old rats, ethanol (50 mM) stimulated GABA release and increased the amplitude of postsynaptic currents upon application, with a second amplitude increase 20--30 min after application of ethanol. Because the secondary increase was blocked by an inhibitor of the enzyme 5α-reductase (finasteride), enzymatic conversion of neuroactive steroids appears to have mediated this effect of ethanol (Sanna et al., [@B168]). These data highlight the possibility of indirect effects of ethanol on GABAergic neurotransmission via steroidogenesis, for which variability in these processes could account for individual differences in sensitivity to ethanol.

Species differences in the efficacy of ethanol to increase neuroactive steroid concentrations have been reported, but procedural differences make comparison difficult. For example, acute ethanol increased plasma neuroactive steroids when given by injection to rodents \[mean blood-ethanol concentration (BEC), 212 mg/dl\] but did not change, or decreased neuroactive steroid concentrations following intragastric administration in macaque monkeys (mean BEC, 125 mg/dl; Porcu et al., [@B152]). Another confound is interactions with innate biological rhythms, as some neuroactive steroids have a diurnal rhythm, similar to cortisol (Weitzman et al., [@B205]). Porcu et al. ([@B153]) demonstrated that, in humans, deoxycorticosterone has a diurnal rhythm in which concentrations are greater in the morning compared to the evening. In contrast, concentrations of pregnenolone sulfate were similar in the morning and evening, suggesting that diurnal activity of specific steroidogenic enzymes could have contributed to deoxycorticosterone concentrations. Whether ethanol affects circulating neuroactive steroid concentrations could depend on the time of day. In one study, young adult men that drank 0.80 g/kg ethanol at 6:00 pm had similar serum concentrations of allopregnanolone (0.145 ng/ml) and pregnenolone (0.297 ng/ml) compared to baseline (0.125 and 0.262 ng/ml, respectively; Porcu et al., [@B152]). In contrast, Pierucci-Lagha et al. ([@B146]) reported that when young adult men drank the same dose of ethanol at 11:00 am, plasma allopregnanolone (0.07 ng/ml) decreased and pregnenolone (4.56 ng/ml) increased compared to baseline (allopregnanolone, 0.13 ng/ml; pregnenolone, 4.05 ng/ml). Further studies of ethanol effects on circulating neuroactive steroids are needed that include a range of BECs and times of day.

Possible species differences in ethanol sensitivity could relate to basal levels of neuroactive steroids. For example, basal pregnenolone was much greater in male cynomolgus monkeys (945 pg/ml) compared to humans (297 pg/ml), male rats (165 pg/ml), or male mice (49 pg/ml), but 3α,5α-THP, 3α,5β-THP, and 3α,5α-THDOC were much lower in cynomolgus monkeys compared to rats, mice, and adult men (Porcu et al., [@B152]). The relatively high basal pregnenolone concentration observed in cynomolgus macaques suggests the potential for high concentrations of pregnenolone sulfate following sulfation that could negatively modulate GABA~A~ receptors (Park-Chung et al., [@B140]) and potentiate NMDA responses to glutamate (Wu et al., [@B210]; Park-Chung et al., [@B141]). High basal pregnenolone may predict a lower potency of ethanol in behavioral assays. For example, 30 and 56 mg/kg pregnenolone decreased responding for ethanol and ethanol consumption in rats (Besheer et al., [@B11]). Although the equivalent primate studies have not been conducted, and the levels of neuroactive metabolites can make interpretation challenging, it is possible that circulating levels of pregnenolone contribute to individual and species differences in the effects of ethanol.

GABA~A~ Receptor-Mediated Inhibitory Signaling
==============================================

GABA~A~ receptor-mediated inhibition can be roughly grouped into two forms, "phasic" and "tonic" inhibition (Cavelier et al., [@B31]; Farrant and Nusser, [@B54]; Glykys and Mody, [@B63]). Phasic inhibition refers to the long known, traditional inhibitory postsynaptic currents (IPSCs), generated by GABA~A~ receptors in the postsynaptic membrane that are transiently activated (hence the term phasic) by vesicular release of GABA. The phasic nature of IPSCs is due to the rapid removal of GABA from the synaptic cleft by diffusion and uptake on plasma-membrane GABA transporters, as well as desensitization of postsynaptic GABA~A~ receptors. Conversely, tonic inhibition is a more recently discovered form of steady state inhibitory current, generated primarily by extrasynaptically located GABA~A~ receptors that are persistently activated (hence the term tonic) by the ambient extracellular concentration of GABA (Hamann et al., [@B78]; Cavelier et al., [@B31]; Farrant and Nusser, [@B54]; Glykys and Mody, [@B63],[@B64]; Choi et al., [@B34]; Lee et al., [@B116]). The extracellular concentration of GABA that drives tonic GABA~A~ inhibition is determined by the balance between GABA release (via vesicle exocytosis and various forms of non-vesicular release) and GABA uptake by GABA transporters (Rossi et al., [@B165]; Glykys and Mody, [@B64]; Lee et al., [@B117]). Accordingly, the magnitude of tonic GABA~A~ inhibition is increased by blocking GABA uptake, and decreased by blocking any of the various forms of GABA release. Conversely, increasing GABA release increases the magnitude of tonic GABA~A~ inhibition. Importantly, since a main source of GABA release is the vesicular release that also generates phasic IPSCs, the magnitude of tonic GABA~A~ inhibition often varies in parallel with changes in IPSC frequency (Glykys and Mody, [@B64]).

The GABA~A~ receptor is composed of five trans-membrane subunits arranged to form an anion-conducting pore, and the makeup of subunits, from a family of 19 unique subunits (α1--6, β1--3, γ1--3, δ, ε, þ, π, and ρ1--3), determines the sub-cellular location of the receptor (synaptic versus extrasynaptic). The subunit composition of GABA~A~ receptors also determines their kinetic and pharmacological properties, including sensitivity to neurosteroids, ethanol, and other GABA~A~ modulatory compounds. Thus, interpreting the behavioral impact and interactions of ethanol and neurosteroids requires an understanding of the subunit properties, and their distribution pattern in various brain regions.

One consistent and important GABA~A~ receptor theme is that δ subunits are located exclusively extrasynaptically, and it is such δ subunit-containing, extrasynaptic GABA~A~ receptors that mediate tonic inhibition (Rossi and Hamann, [@B164]; Hamann et al., [@B78]; Stell et al., [@B189]; Farrant and Nusser, [@B54]; Kelm et al., [@B107]). The δ subunit is primarily expressed by a limited number of cell types in a few brain regions, including cerebellar and hippocampal granule cells, thalamic relay neurons, and possibly more restrictedly in subsets of cells elsewhere, including non-granule hippocampal cells and some cortical cells (Wisden et al., [@B207]). Thus, tonic inhibition is generally restricted to specific cell types in particular brain regions. In these brain regions the δ subunit generally pairs with α~4~ or α~6~ subunits, which together endows the parent receptor with properties idealized for sensing ambient GABA to generate tonic inhibition: a higher affinity for GABA and less receptor desensitization than other subtypes of GABA~A~ receptors (Saxena and Macdonald, [@B171], [@B172]). However, although the δ subunit is solely expressed extrasynaptically and typically co-assembles with α~4~ or α~6~ subunits, the latter subunits can also be part of functional, synaptic receptors that do not contain δ subunits. Thus, while pharmacological or genetic manipulations of the δ subunit can be unambiguously attributed to effects on tonic GABA~A~ inhibition, α~4~- or α~6~-specific manipulations may affect synaptic transmission (i.e., IPSCs), extrasynaptic transmission (i.e., tonic inhibition), or both. On the other hand, the α~6~ subunit is expressed almost exclusively by cerebellar granule cells, making actions of α~6~-specific manipulations attributable to actions at cerebellar granule cells. Other than the α~5~ subunit, which is largely restricted to the hippocampus and cortex, the rest of the GABA~A~ subunits are more ubiquitously expressed making attribution of subunit-specific manipulations to specific brain region processing more complicated. Finally, although expression of the δ subunit is restricted to only a few brain regions, because of the constant nature of the tonic inhibition they generate, tonic inhibition is significantly more powerful than phasic inhibition, mediating \~75% of total inhibition in cells that exhibit tonic inhibition (Hamann et al., [@B78]). Thus, the δ subunit is potentially a powerful target for neural modulation.

Neurosteroid Actions at GABA~A~ Receptors
=========================================

As described in the introduction, at physiologically relevant concentrations, neurosteroids can either potently enhance GABA~A~ receptor function, or, in the case of sulfated neurosteroids, powerfully suppress them. The diversity of neurosteroids combined with their potency and respective abilities to enhance or suppress GABA~A~ receptor function enables a powerful fine-tuning of the GABA~A~ system across behavioral states and across brain regions. Early behavioral and electrophysiological studies suggested that the δ subunit played a crucial role in mediating the actions of neurosteroids, with many studies indicating that the δ subunit imparted an increased sensitivity to neurosteroids (Mihalek et al., [@B129]; Belelli et al., [@B9]; Wohlfarth et al., [@B208]; Stell et al., [@B189]), although other studies suggested that the δ subunit decreased sensitivity to neurosteroids (Zhu et al., [@B212]; Hamann et al., [@B78]). However, more recent work on recombinant GABA~A~ receptors has determined that there is a conserved neurosteroid binding site on α subunits (α~1--5~; Hosie et al., [@B94]). Thus, because all GABA~A~ receptors contain α subunits, neurosteroids are potent modulators of most, if not all, known GABA~A~ receptors, regardless of subunit makeup. Such studies suggested that earlier data implicating the δ subunit in neurosteroid sensitivity resulted from the δ subunit increasing neurosteroid efficacy rather than receptor affinity for neurosteroids. Thus, in principle, systemic neurosteroids could impact both phasic and tonic GABA~A~ inhibition throughout the brain, and selective actions on particular cell types could be dependent on local synthesis. Nonetheless, *in situ* studies showed that very low concentrations of exogenous neurosteroid (\<20 nM) powerfully enhanced tonic GABA~A~ currents but not phasic GABA~A~ currents in the same preparation, and that knocking out the δ subunit eliminated tonic GABA~A~ current sensitivity to neurosteroids (Stell et al., [@B189]). The contrast with data from recombinant receptors suggests that *in situ* receptors may behave differently, and that the δ subunit does affect receptor affinity *in situ*. In fact, studies examining GABA~A~ currents in different brain regions indicate that the sensitivity of both phasic and tonic GABA~A~ currents to neurosteroids varies across cell types, even when apparently identical GABA~A~ receptor subunits are involved (Belelli et al., [@B10]). Such variability may be due to the phosphorylation state of the GABA~A~ receptor and/or local neurosteroid metabolism, two factors that add further control and complexity to neurosteroid actions at GABA~A~ receptors. Thus, although the presence of the δ subunit or specific α, β, or γ subunit may impart subtle differences to the parent receptor that are physiologically relevant, it is unlikely that exogenous neurosteroids can be used as subunit-selective modulators to identify crucial subunits or brain regions involved in a particular behavioral response. Similarly, if selective modulation of a specific GABA~A~ subunit (such as genetic deletion) has a significant impact on a behavioral response to neurosteroids, it should be interpreted with respect to the importance of the brain region(s) in which the subunit is expressed to the behavior, rather than to the particular sensitivity of the subunit to neurosteroids.

Ethanol Actions at GABA~A~ Receptors
====================================

Ethanol has also long been known to be a potent enhancer of GABA~A~ receptor-mediated inhibition, but identifying the mechanism(s) of action has been controversial, and is clearly even more complex than for neurosteroid modulation. Several groups have reported that concentrations of ethanol that are likely to be achieved during moderate to abusive drinking (5--50 mM) can enhance tonic GABA~A~ inhibition via directly increasing the affinity of certain GABA~A~ receptors for GABA, including α~6~βδ subunits in cerebellar granule cells, α~4~βδ subunits in hippocampal granule cells and thalamic relay neurons, and α~1~βδ subunits in hippocampal interneurons (Wei et al., [@B204]; Hanchar et al., [@B79]; Glykys et al., [@B65]). Most of the studies showing direct actions of ethanol on GABA~A~ receptors have observed this effect in receptors containing the δ subunit, leading to the notion that the δ subunit containing GABA~A~ receptors are low-dose ethanol receptors (Hanchar et al., [@B80]; Olsen et al., [@B138]; Mody, [@B130]). Unfortunately, demonstration of direct actions of ethanol on GABA~A~ receptors has been difficult to replicate, and most researchers, using similar, nearly identical techniques and preparations have been unable to show any direct actions of ethanol on GABA~A~ receptors of any composition (Borghese et al., [@B15]; Borghese and Harris, [@B14]; Botta et al., [@B16],[@B17]). Despite intensive efforts, the reasons for this discrepancy have not yet been elucidated. One factor may relate, at least in part, to the phosphorylation status of the GABA~A~ receptor, similar to neurosteroids. In particular, Choi et al. ([@B34]) determined that enhancement of tonic GABA~A~ currents mediated by GABA~A~ receptors containing α~4~δ subunits required that the receptor be phosphorylated by protein kinase (PK) Cδ, and accordingly, knocking out PKCδ prevented ethanol from enhancing tonic GABA~A~ currents in hippocampus and thalamus, and reduced behavioral sensitivity to ethanol. While it is not clear why the phosphorylation status of the GABA~A~ receptor would be so starkly different across laboratories, it does provide a potential mechanism explaining in part the discrepant observations across laboratories regarding direct actions of ethanol on GABA~A~ receptor currents. Intriguingly, although PKCδ expression correlates with the GABA~A~ δ subunit expression in hippocampus and thalamus, it is not expressed in the cerebellar granule cell layer, where α~6~δ subunits are expressed. This raises the possibility that if phosphorylation status explains the discrepant observations of ethanol-induced potentiation of tonic GABA~A~ currents in cerebellar granule cells, there must be kinases other than PKCδ to serve that role in the cerebellar granule cell layer.

In addition to the potential direct action of ethanol on some GABA~A~ receptors, it is widely accepted that ethanol strongly enhances vesicular release of GABA. As a result, the frequency of IPSCs increases and, in cells that express extrasynaptic GABA~A~ receptors, the magnitude of tonic GABA~A~ currents is strongly enhanced due to the accumulation of vesicular release of GABA in the extrasynaptic space. This mechanism is observed in many brain regions, including the cerebellum, ventral tegmental area, substantia nigra, and amygdala, but lacking in others, including cortex, lateral septum, and thalamus (Kelm et al., [@B108]). The mechanisms underlying ethanol-induced vesicular GABA release are not fully understood, but often appears to involve G-protein coupled receptor systems (Kelm et al., [@B108]). Thus, regardless of whether ethanol acts directly on GABA~A~ receptors, ethanol can increase both the frequency of IPSCs as well as the magnitude of the tonic GABA~A~ current. Therefore, even if ethanol does not directly affect δ subunits in a particular brain region or under particular conditions, knocking out (or selectively modifying) the δ subunit could still strongly influence the response to ethanol, because the lack of extrasynaptic GABA~A~ receptors will eliminate tonic GABA~A~ currents that would normally be generated by increased vesicular release of GABA.

Interactions between Neurosteroids and Ethanol at GABA~A~ Receptors
===================================================================

Given that neurosteroids and ethanol converge on GABA~A~ receptors, it is worth considering how they may interact with each other at the GABA~A~ receptor. Given the more consistent and ubiquitous direct actions of neurosteroids on GABA~A~ receptors compared to ethanol, it seems unlikely that the two compounds share a binding site, and thus will not compete or interact directly. It is, however, possible that for those GABA~A~ receptors that are directly modulated by both neurosteroids and ethanol (see above), combined exposure will have a synergistic or other interactive impact. However, to our knowledge there are no reports of such interactions, and given current controversies about direct actions for both ethanol and neuroactive steroids, it may be difficult to ascertain such interactions at the receptor level. Perhaps the most obvious way in which neurosteroids and ethanol are likely to interact at the GABA~A~ receptor is via ethanol-induced increase in vesicular GABA release as described above. It is clear that neurosteroid effects on GABA~A~ receptors are relatively ubiquitous across receptors with different subunit compositions. Therefore, it is likely that neurosteroids will be active at GABA~A~ receptors in brain regions in which ethanol increases GABA release. Indeed, there is overlap between the documented actions of neurosteroids at GABA~A~ receptors and documented ethanol-induced vesicular GABA release in the cerebellum, hippocampus, thalamus, and amygdala (Hamann et al., [@B78]; Stell et al., [@B189]; Carta et al., [@B30]; Belelli et al., [@B10]; Criswell et al., [@B38]; Kelm et al., [@B107], [@B108]). Accordingly, in those brain regions, since neurosteroids enhance the actions of GABA at GABA~A~ receptors and ethanol enhances GABA release, there will likely be a synergistic interaction if cells in those brain regions are exposed to both simultaneously. Importantly, since ethanol increases neurosteroid release both systemically and locally (see earlier sections), such a synergistic enhancement of GABA~A~ currents is likely. Irrespective of the cellular/molecular mechanisms at play, since both neurosteroids and ethanol enhance GABA~A~ currents, it is likely that they may substitute for each other behaviorally. Whereas both tonic and phasic inhibition may decrease the magnitude and duration of excitatory input, because tonic inhibition is persistent and distributed, it may increase the threshold of depolarization required for a cell to fire (Farrant and Kaila, [@B53], p. 70). This leads to the hypothesis that neurosteroids and ethanol could modulate the threshold for stimulation by sensory input by enhancing tonic inhibition in brain areas containing δ subunits, whereas the activity of neurosteroids and ethanol in other brain areas could affect the magnitude of physiological or behavioral response to a stimulus.

Common Receptor Activity of Ethanol and Neuroactive Steroids: Evidence from Behavioral Pharmacology
===================================================================================================

Changes in sensory thresholds are a major aspect of sleep, which involves modulation of thalamocortical excitability (Huguenard and McCormick, [@B98]). Ethanol (50 mM) has been shown to suppress the activity of thalamocortical relay neurons (Jia et al., [@B100]), and as described above, these contain δ subunits. However, few studies have examined the interactive effects of ethanol and neuroactive steroids on psychophysical parameters and these have mainly been restricted to response magnitude or latency, rather than response threshold. Nonetheless, the idea that the effects of ethanol on sensorimotor processing are influenced by neuroactive steroids is not well-supported by the limited data available. For example, a very high dose of ethanol (5.25 g/kg, i.g.) administered to rats on post-natal days 4--9 did not alter the magnitude of startle to a 110-db noise, or the attenuation of this startle by a preceding 60-db tone (i.e., prepulse inhibition) compared to vehicle controls when the animals were tested as adolescents or adults (70 days of age; Woolfrey et al., [@B209]). A single study of neuroactive steroids in healthy women found that neither startle magnitude nor prepulse inhibition were affected by allopregnanolone (0.05 mg/kg; Kask et al., [@B102]). In contrast, the magnitude of prepulse inhibition was increased in adult rats by administration of allopregnanolone (but not pregnenolone sulfate) to hippocampal CA1 (Darbra et al., [@B41]), but decreased by systemic administration of allopregnanolone (10 mg/kg) during post-natal days 5--9 (Darbra and Pallarès, [@B42]). Thus, administration of allopregnanolone (Darbra and Pallarès, [@B42]) but not ethanol (Woolfrey et al., [@B209]) to neonates decreased prepulse inhibition in adulthood, at least at the doses tested. Because none of these studies examined the interaction between ethanol and neuroactive steroids, it is unknown whether neuroactive steroids could have a modulatory role under conditions in which ethanol decreased arousal and stimulus processing.

Another set of studies measured cortical electrical responses after presentation of auditory stimuli (event-related potentials, ERPs). Allopregnanolone and ethanol decreased the amplitude of ERPs in the cortex and amygdala, consistent with decreased stimulus efficacy (Slawecki et al., [@B186]). The same study found that the combination of sub-threshold doses of allopregnanolone (5.0 mg/kg) and ethanol (0.50 g/kg) decreased peak amplitudes in the amygdala, indicative of decreased arousal, but no additive effects were observed in the cortex. Ethanol vapor inhalation for 14 h/day for 5 weeks did not affect ERPs, but tolerance developed to the decrease in ERPs produced by allopregnanolone (Slawecki et al., [@B185]), suggesting that chronic ethanol exposure caused molecular adaptations of GABA~A~ receptors (e.g., subunit composition) resulting in altered neurosteroid pharmacology/sensitivity (Liang et al., [@B120]). To our knowledge, there are no studies of ERPs in humans evaluating the interaction between neuroactive steroids and ethanol. Overall, these limited data suggest that the additive effects of ethanol and neuroactive steroids on neural activity depend on the brain region examined, which could be due to the localization of ethanol-induced GABA release, or to the presence or absence of specific GABA~A~ receptor subunits, including those that mediate tonic inhibition.

A much more extensive body of behavioral data that addresses common receptor activity of ethanol and neuroactive steroids includes consummatory behaviors and discriminative stimulus effects. Neurons within the circuitry mediating contextual, reinforcing, or other stimulus properties of ethanol are likely to regulate ethanol consumption. The threshold at which ethanol-associated stimuli affect neurotransmission could be modulated by neurosteroids, thus providing a mechanism by which neuroactive steroids regulate ethanol intake. With regard to consummatory behavior, compared to vehicle administration, mice administered the direct GABA~A~ agonist gaboxadol \[4,5,6,7-tetrahydroisoxazolo (5,4-c)pyridin-3(-ol); THIP\] at a dose (8 mg/kg) presumably selective for δ-containing GABA~A~ receptors, showed a selective decrease in ethanol (not water) intake, and a lower latency to drink either solution (Ramaker et al., [@B158]). These data implicate extrasynaptic GABA~A~ receptors in regulating consummatory behavior generally (Kelley et al., [@B104]), and further suggest that tonic GABA~A~ inhibition can selectively regulate ethanol intake. Thus, the ability of neuroactive steroids to modulate tonic inhibition could make them therapeutically useful for alcohol abuse. Consistent with this possibility, neuroactive steroids are associated with the conditioned aspects of consummatory behavior. For example, anticipation and consumption of food increased plasma and cerebrocortical allopregnanolone and THDOC (Pisu et al., [@B148]). Because Ramaker et al. ([@B158]) did not measure response thresholds with gaboxadol, nor was there a measure of conditioned stimulus effects that could regulate drinking, the behavioral processes affected by gaboxadol that underlie the decrease in ethanol intake are not clear. Gaboxadol-induced tonic currents in cerebellar granule cells (α~6~δ; Meera et al., [@B126]) and thalamic neurons (Herd et al., [@B87]) are greatly reduced in δ knockout mice, indicating that this subunit is important for sensitivity to gaboxadol. Another study suggested that δ subunits in the striatum are involved in ethanol drinking. Nie et al. ([@B136]) used viral-mediated RNA interference to decrease GABA~A~ receptor δ subunit mRNA and protein approximately two-fold in the medial nucleus accumbens shell. Eighteen days after infusion, ethanol but not sucrose intake under intermittent access decreased from an average of 4.5 g/kg/day to 2.5 g/kg/day. Suppression of δ subunits in the medial shell was suggested to decrease ethanol-induced potentiation of tonic inhibition in a brain area that mediates ethanol reinforcement. By extension, variation in δ subunit expression in the medial shell and perhaps potentiation of tonic inhibition by neurosteroids could be mechanisms for variation of ethanol effects within and across individuals.

By far, the greatest amount of data addressing the role of neuroactive steroids in sensitivity to ethanol has been obtained using drug discrimination procedures. In these procedures, a specific response is reinforced (e.g., pressing the one of two levers results in food presentation) following administration of a given dose of a drug such as ethanol, and another response (e.g., pressing the other lever) is reinforced following administration of vehicle. The animal's perception of the effect of the drug is the only cue guiding its choice of which response to perform. Once the animals reliably respond on the drug-associated lever after training drug administration, test drugs can be administered. A test drug may be shown to substitute for the training drug, i.e., produce responding on the lever associated with the training drug, indicating similar discriminative stimulus effects. Threshold and magnitude of response can be dissociated in drug discrimination data by potency (effective dose, ED~50~) and efficacy (maximum responding on the ethanol lever), respectively. Discrimination of the stimulus effects of drugs can be trained in humans using the same operant techniques. Drugs that positively modulate GABA~A~ receptors, including ethanol, and produce similar discriminative stimulus effects also tend to produce common subjective effects in humans (Kelly et al., [@B106]).

Studies in non-human primates indicate that the discriminative stimulus effects of a wide range of ethanol doses (1.0--2.0 g/kg) are mediated largely by GABA~A~ receptors (Grant et al., [@B74]; Vivian et al., [@B198]; Helms et al., [@B84]). In contrast, the discriminative stimulus effects of higher doses of ethanol (2.0 g/kg) appear to involve specific subtypes of GABA~A~ receptors (i.e., zolpidem-sensitive α~1~-containing; Helms et al., [@B85]). The discriminative stimulus effects of 5 mg/kg pregnanolone are also mediated by positive modulation of GABA~A~ receptors. For example, in rats trained to discriminate pregnanolone, high levels of responding on the pregnanolone-appropriate lever occurred after administration of benzodiazepines and barbiturates, which are positive modulators of GABA~A~ receptors. In contrast, the direct agonists muscimol and gaboxadol produced low levels of pregnanolone-appropriate responding (Engel et al., [@B50]). Thus, the discriminative stimulus effects produced by GABA~A~ receptor agonists and positive modulators are distinct. Consistent with this conclusion, in animals trained to discriminate ethanol, the direct agonists muscimol and gaboxadol do not produce ethanol-like effects (cynomolgus monkeys, Grant et al., [@B74]; mice, Shelton and Grant, [@B181]). The activity of gaboxadol as an agonist rather than a positive modulator may account for its lack of ethanol-like stimulus effects. On the other hand, if infused directly into the nucleus accumbens or amygdala, muscimol can substitute for the discriminative stimulus effects of peripherally administered ethanol in rats (Hodge and Cox, [@B89]). Taken together, these data suggest that, although neurosteroids can directly activate GABA currents at high concentrations (Hosie et al., [@B95]), ethanol-like discriminative stimulus effects occur at lower, positive-modulatory concentrations. Second, interactions among specific brain regions may contribute to the discriminative stimulus effects of ethanol. For example, Hodge et al. ([@B90]) found that allopregnanolone substituted for the discriminative stimulus effects of systemic ethanol when administered into the nucleus accumbens but not the hippocampus (CA1). Thus, hippocampal CA1 neurons that are sensitive to neurosteroids may not be involved in ethanol-like discriminative stimulus effects.

The GABA~A~ receptor subtypes at which neuroactive steroids produce discriminative stimulus effects similar to ethanol have not been extensively investigated. In one study, δ subunit knockout mice learned to discriminate 1.5 g/kg ethanol, and showed similar substitution of neuroactive steroids (pregnanolone and alphaxalone) for the discriminative stimulus effects of ethanol (Shannon et al., [@B179]). Thus, δ subunits do not appear to be necessary for the ethanol-like discriminative stimulus effects of neuroactive steroids. Zolpidem is an imidazopyridine with selectivity for α~1~-containing GABA~A~ receptors (Lüddens et al., [@B123]), which combine with γ subunits and are purported to be primarily synaptic, although co-assembly with δ subunits and mediation of tonic currents has been observed in interneurons of the hippocampus (Glykys et al., [@B65]). Predominantly, however, α~1~-containing receptors are synaptic and therefore mediate phasic GABA neurotransmission. In drug discrimination procedures, zolpidem substituted for the discriminative stimulus effects of pregnanolone in rats (Engel et al., [@B50]) but not mice (Shannon et al., [@B177],[@B178]), and no data exist for primates. Zolpidem partially substituted for ethanol in rats (Sanger et al., [@B167]) but not mice (Shannon et al., [@B179]) and completely substituted for 2.0 g/kg ethanol in cynomolgus monkeys (Helms et al., [@B85]). Overall, these data suggest that α~1~ subunits could mediate the discriminative stimulus effects of both ethanol and neuroactive steroids under some conditions. However, whether this subunit is involved in the ethanol-like effects of neuroactive steroids has not been studied. Finally, using the 5α-reductase inhibitor finasteride, the subjective effects of ethanol (0.7--0.8 g/kg, BEC, 50--70 mg/dl) were attenuated in humans, but only in individuals homozygous for the A (but not the G) allele at the GABA~A~ receptor α~2~ subunit gene (Pierucci-Lagha et al., [@B147]). These data suggest that the subjective effects of ethanol are enhanced by neuroactive steroids in a select population carrying a polymorphism in the α~2~ subunit of the GABA~A~ receptor. The role of α~2~ subunits in the discriminative stimulus effects of ethanol and neuroactive steroids has not been explored due to a lack of drugs with appropriate selectivity.

The GABA~A~ receptors mediating the ethanol-like effects of neuroactive steroids have been studied using pharmacological antagonism. Ro15-4513 is a partial inverse agonist with high affinity for receptors containing α~4~, α~5~, or α~6~ subunits and lower affinity for α~1~, α~2~, or α~3~ subunits. This drug is celebrated as a competitive antagonist of the electrophysiological and behavioral effects of ethanol (Suzdak et al., [@B191]; Wallner and Olsen, [@B200]). In drug discrimination studies, we found that Ro15-4513 antagonized the substitution of allopregnanolone and pregnanolone for the discriminative stimulus effects of ethanol (Figure [2](#F2){ref-type="fig"}). Antagonism of pregnanolone substitution for ethanol was observed in 6/6 monkeys trained to discriminate 1.0 g/kg ethanol, and in 3/5 monkeys trained to discriminate 2.0 g/kg ethanol. Ro15-4513 antagonized allopregnanolone substitution for ethanol in 3/6 monkeys trained to discriminate 1.0 g/kg ethanol, and 4/5 monkeys trained to discriminate 2.0 g/kg ethanol. Among the monkeys showing antagonism, Ro15-4513 resulted in decreased potency, but not efficacy, of these neuroactive steroids to substitute for ethanol. In addition, according to an apparent pA2 analysis (Rowlett and Woolverton, [@B166]), the estimated affinity of Ro15-4513 for the receptor population mediating substitution of pregnanolone (pK~B~ of 5.2--7.0) and allopregnanolone (pK~B~ of 6.1--8.9) overlapped with zolpidem (pK~B~ of 6.3--8.0). These affinity estimates suggest that pregnanolone and allopregnanolone act at benzodiazepine-sensitive and -insensitive GABA~A~ receptors to produce discriminative stimulus effects similar to ethanol. Because the γ subunit is obligatory for benzodiazepine sensitivity and this subunit is primarily synaptic (Möhler, [@B131]), these data suggest that the ethanol-like discriminative stimulus effects of neuroactive steroids are mediated by synaptically located GABA~A~ receptors that regulate phasic inhibition.

![**Among male (*n* = 6) and female (*n* = 6) cynomolgus macaques that were trained to discriminate 1.0 or 2.0 g/kg ethanol, pregnanolone produced ethanol-like discriminative stimulus effects in all monkeys, which were antagonized when Ro15-4513 (symbols indicate doses in mg/kg, i.m.) was administered after pregnanolone, 5 min before the levers extended into the chamber**. Shifts in the dose-response curves of four monkeys are shown.](fendo-03-00010-g002){#F2}

In contrast to the ethanol-like effects of positive modulators of GABA~A~ receptors, neuroactive steroids that negatively modulate GABA~A~ receptors, including epipregnanolone and epiallopregnanolone sulfate, might antagonize the discriminative stimulus effects of ethanol. Our preliminary data indicate that epipregnanolone (0, 10, 17, 30 mg/kg, s.c.) and epiallopregnanolone (0, 17, 30 mg/kg, s.c.) administered 30 min prior to ethanol (0.25--2.5 g/kg, i.g.) blocked (≤20% ethanol-appropriate) discriminative effects in only a subset of cynomolgus monkeys. Specifically, epipregnanolone blocked the discriminative stimulus effects of ethanol in 1/6 of monkeys trained to discriminate 1.0 g/kg ethanol, and in 2/6 monkeys trained to discriminate 2.0 g/kg ethanol. In another study in rats, administration of epipregnanolone (10--20 mg/kg, i.p.) decreased responses for ethanol measured over 30 min from 40 to 20 (O'Dell et al., [@B137]). Although preliminary, these data suggest that neuroactive steroid negative modulators could block the subjective effects of ethanol and consequently responding for ethanol, and thus could be therapeutic targets. However, these data are also consistent with the wide individual differences in the substitution patterns of neuroactive steroids (e.g., Bowen et al., [@B18]; Grant et al., [@B72]), the causes of which are currently unknown. Some possible sources of individual differences in the modulation of ethanol effects by neuroactive steroids could be basal hormone concentration, polymorphisms in GABA~A~ receptor subunits, basal activity of steroidogenic enzymes, reproductive state, or the effects of stress on HPA axis function.

Many studies have indicated that physiological concentrations of the neuroactive steroids allopregnanolone and pregnanolone substitute for the discriminative stimulus effects of ethanol (Grant et al., [@B70], [@B71], [@B72]; Bowen et al., [@B18]). These findings suggest that endogenous variation in neuroactive steroids could influence sensitivity to ethanol. Indeed, the potency of 1.0 g/kg ethanol (Grant et al., [@B71]) but not 2.0 g/kg ethanol (Green et al., [@B75]) to produce discriminative stimulus effects was greater during the luteal compared to the follicular phase of the menstrual cycle in monkeys. During the luteal phase, peak progesterone concentration is associated with greater circulating concentrations of progesterone-derived neuroactive steroids, including allopregnanolone and pregnanolone (Genazzani et al., [@B61]; Hill et al., [@B88]). Although self-reported subjective effects of low ethanol doses (up to 0.6 g/kg) did not vary across a menstrual cycle in women (Holdstock and de Wit, [@B91]), sensitivity to the benzodiazepine triazolam was greater during women's luteal compared to the follicular phase when measured using a drug discrimination procedure (Kelly et al., [@B105]). Despite the absence of menstrual cycles in males, male and female cynomolgus monkeys show only minor differences in the ethanol-like discriminative stimulus effects of neuroactive steroids. For example, the potency of androsterone to produce ethanol-like stimulus effects is on average lower in males compared to females (Grant et al., [@B73]). In humans, subjective effects associated with varying plasma concentrations of neuroactive steroids could contribute to regulation of ethanol consumption. For example, change in plasma neuroactive steroid concentration after consuming 0.80 g/kg ethanol (11:00 am) correlated significantly with subjective effects of ethanol including "liking" (pregnenolone, *r* = 0.53; allopregnanolone, *r* = 0.50) and "want more alcohol" (*r* = 0.51; Pierucci-Lagha et al., [@B146]). These data further suggest that neuroactive steroids produced as a result of ethanol self-administration could subsequently regulate intake. By extension, the effects of ethanol may vary with other endogenous (e.g., stress: Droogleever Fortuyn et al., [@B48]) or disease states (e.g., premenstrual dysphoric disorder, Bäckström et al., [@B7]) associated with altered concentration of, or sensitivity to, GABAergic neuroactive steroids. Such endogenous conditions could influence the risk of alcohol abuse.

The Role of Neuroactive Steroids in Chronic Ethanol Effects and Ethanol Withdrawal
==================================================================================

Although naïve individuals differ in sensitivity to the acute effects of ethanol, a much greater variability in sensitivity to ethanol occurs within individuals as a result of repeated administration. Neuroadaptation to chronic ethanol involves decreased sensitivity to GABA and changes in GABA~A~ receptor subunit expression and function. These neuroadaptations have additional pharmacological consequences including decreased sensitivity to benzodiazepines and increased sensitivity to some neuroactive steroids (reviewed by Biggio et al., [@B13]). Changes in subunit expression after ethanol or progesterone withdrawal differ between brain areas (cerebral cortex, cerebellum, and hippocampus are most often studied), but a relatively consistent result is decreased expression of α~1~ and δ subunits and increased expression of α~4~ and α~6~ subunits (Mhatre and Ticku, [@B128]; Rani and Ticku, [@B159]). Electrophysiological studies in cultured neurons have confirmed that the changes in GABA~A~ receptor subunits after chronic ethanol treatment and withdrawal are associated with changes in receptor function (reviewed by Kumar et al., [@B111]). In a report by Shen et al. ([@B184]), endocytosis of GABA~A~ receptors containing α~4~ and δ subunits was shown to be increased by ethanol treatment in cultured hippocampal neurons. In another model, rats are administered high doses of ethanol intermittently (chronic intermittent ethanol, CIE: 5 g/kg every other day for 5 days, then 6 g/kg/day for 55 days) and then brain slices are prepared for electrophysiology. The CIE treatment results in the decreased efficacy of several GABAergic sedative/hypnotic drugs (e.g., ethanol, zolpidem, gaboxadol) to potentiate tonic currents in hippocampal slices (Liang et al., [@B119], [@B120]). At the same time, these drugs showed greater efficacy to potentiate phasic (synaptic) currents after CIE. This result was related to decreased α~1~ subunits at synaptic sites, decreased α~4~, β, and δ subunit protein at extrasynaptic sites, and increased α~4~, β, and γ~2~ subunits at synaptic sites (Liang et al., [@B119], [@B120]). Notably, similar to the effects of withdrawal from chronic ethanol, increased α~4~ subunit expression is observed in the hippocampus after chronic allopregnanolone and withdrawal (reviewed by Smith et al., [@B187]). Overall, these data suggest that the neuroadaptations to chronic ethanol and neuroactive steroids are similar, possibly to maintain homeostasis of inhibitory neurotransmission. Regardless of the mechanisms by which it is accomplished, i.e., direct receptor action by neuroactive steroids or increased GABA release by ethanol, positive modulation of GABA~A~ receptors appears to be a common effect of ethanol and exogenous neuroactive steroids that can result in homeostatic molecular adaptations to restore GABAergic tone. Such homeostatic adaptations result in withdrawal following the removal of neurosteroids or ethanol.

The great complexity of results from *in vitro* studies, in which differences are commonly found between brain areas, suggests that *in vivo* pharmacological studies could inform changes in GABA~A~ receptor function after chronic ethanol and withdrawal. For example, 10 mg/kg alphaxalone induced sleep, as measured by a loss of righting reflex. After CIE, however, the duration of sleep induced by alphaxalone was decreased, indicating cross-tolerance (Cagetti et al., [@B27]). In contrast, the efficacy of alphaxalone to increase time spent on the open arms in the elevated plus maze (purportedly an anxiolytic effect) was increased after CIE (Cagetti et al., [@B28]). In the same study, rats exposed to CIE were sensitized to the convulsant effect of pentylenetetrazol, as 20--25 mg/kg induced seizures in this group compared to 40 mg/kg in control rats. This treatment also resulted in greater sensitivity to the anticonvulsant effects of alphaxalone. Likewise, the anticonvulsant efficacy and potency of allopregnanolone (Devaud et al., [@B46]) and THDOC (Devaud et al., [@B45]) was increased by chronic ethanol treatment in rats (liquid diet, 10--12 g/kg/day for 14 days) and mice (72 h ethanol vapor inhalation, Finn et al., [@B57]). These data indicate that chronic ethanol and withdrawal are associated with increased sensitivity, rather than cross-tolerance, to the anticonvulsant and possibly the anxiolytic effects of GABAergic neuroactive steroids. Thus, data from the limited studies conducted so far suggest that adaptations to chronic ethanol and withdrawal alter the effects of neuroactive steroids in a behavior-specific manner likely related to the GABA~A~ receptor subunits expressed in the brain regions mediating the behavior that is being studied.

Neuroactive Steroid Regulation of the HPA Axis and Interactions with Ethanol
============================================================================

Similar to the negative feedback of the HPA axis by glucocorticoids, GABA is a primary regulator of hypothalamic responses to stress. Activity of the HPA axis, beginning with secretion of CRH, is inhibited by GABA (Calogero et al., [@B29]). Decreased GABAergic activity during acute stress (Biggio et al., [@B12]) results in stimulation of the HPA axis and increased brain and plasma concentrations of neuroactive steroids, at least in rodents (Purdy et al., [@B157]). A variety of stressors have been shown to increase plasma and/or brain neuroactive steroids to concentrations that modulate GABA~A~ receptors *in vitro* (Belelli et al., [@B9]). For example, swim stress (22°C, 10 min) in rats increased allopregnanolone in plasma (\<1 ng/ml to 2.5 ng/ml after 70 min) and brain (cerebral cortex, 2.5 ng/ml to 5 ng/ml after 10 min; hypothalamus, \<2 ng/ml to 4.5 ng/ml after 40 min; Purdy et al., [@B157]). Similarly, plasma allopregnanolone increased from 1.0 to 1.2 nmol/l during oral defense for a Ph.D. degree (Droogleever Fortuyn et al., [@B48]). Increased neuroactive steroids are proposed to dampen the physiological impact of the stress and mediate restoration of homeostasis of the HPA axis (Finn and Purdy, [@B58]). For example, allopregnanolone decreased anxiety in response to heat stress and administration of CRH (Patchev et al., [@B143], [@B142]). A recent report indicated that physiological concentrations of allopregnanolone, THDOC, and pregnenolone in cell culture inhibited CRH reporter gene activity and forskolin-stimulated transcription (Budziszewska et al., [@B25]). Overall, these data are consistent with the idea that endogenous GABAergic neuroactive steroids exert negative feedback on stress responses. Chronic stress has been proposed to result in adaptations of the HPA axis that increase risk for alcohol abuse (Lovallo et al., [@B121]; Biggio et al., [@B13]). Neuroactive steroids may be a target for amelioration of HPA axis abnormalities.

The interaction between neuroactive steroids, ethanol, and chronic stress has been extensively investigated using the social isolation model in which rodents are housed individually after weaning. Compared to group-housed rats, socially isolated rats had lower cortical and plasma concentrations of pregnenolone, progesterone, THDOC and allopregnanolone, and 32% greater basal concentration of plasma corticosterone (Serra et al., [@B176]). After acute ethanol (1.0 g/kg), however, socially isolated rats had greater concentrations of plasma and cerebral cortex pregnenolone, progesterone, allopregnanolone, and THDOC compared to group-housed rats (Serra et al., [@B175]). The chronic stress of social isolation therefore down-regulated the basal concentration of neurosteroids, perhaps lowering inhibitory control of the HPA axis, resulting in greater corticosterone. Furthermore, the efficacy of ethanol to increase neuroactive steroids was greater following social isolation, perhaps related to suppressed basal concentrations. In contrast, following treatment with chronic ethanol (8--10 g/kg/day for 7 days), the efficacy of ethanol to increase plasma concentrations of neuroactive steroids was lower compared to control diet (Boyd et al., [@B19]). Insofar as stress substitutes for, and has additive effects toward, social anxiety induced by ethanol withdrawal (5 days ethanol diet, restraint stress; Breese et al., [@B21]), one hypothesis is that ethanol withdrawal may have effects similar to stress, and potentiate the increase in neuroactive steroid concentration after acute ethanol. To our knowledge, the effects of ethanol withdrawal on the efficacy of acute ethanol to alter concentrations of neuroactive steroids have not been studied.

Sanna et al. ([@B169]) hypothesized that, in socially isolated mice, ethanol drinking would normalize neurosteroid concentrations. Data supporting this hypothesis would suggest that increased neuroactive steroids resulting from consumption of ethanol might contribute to reinforcement of ethanol drinking. This hypothesis was previously investigated by Janak et al. ([@B99]), showing that 3 mg/kg allopregnanolone slightly increased ethanol self-administration from 0.30 to 0.43 g/kg/30 min session. However, Sanna et al. ([@B169]) reported that hippocampal allopregnanolone concentration did not differ between mice consuming ethanol (group-housed, 3.5 g/kg/2 h session; socially isolated, 4.25 g/kg/2 h session) or water for 6 weeks, and remained lower in socially isolated (11--13 ng/g) compared to group-housed mice (15--17 ng/g). Thus, ethanol consumption did not normalize hippocampal (Sanna et al., [@B169]) or cerebral cortical (rats, Pisu et al., [@B149]) neurosteroids that were suppressed by the chronic stress of social isolation. However, there may be differences between voluntary and experimenter-administered ethanol. The proceedings of the 2008 Volterra symposium (Morrow et al., [@B132]) reported that Biggio's lab observed a two-fold increase in cortical allopregnanolone in socially isolated rats exposed to intermittent ethanol vapor for 8 days (BEC, 205 mg/dl at sacrifice; 91% increase in group-housed rats). It may be that compensatory processes induced by ethanol-conditioned stimuli during voluntary drinking maintain neurosteroid homeostasis, similar to neurosteroid regulation by the anticipation of food (Pisu et al., [@B148]).

Changes in the expression of GABA~A~ receptor subunits during chronic stress or ethanol appear to alter GABA~A~ receptor-mediated tonic currents. As a result, changes in the ability of neuroactive steroids to modulate tonic currents might influence the threshold for HPA axis stimulation. In support of this idea, socially isolated rats showed greater expression of α~4~ and δ subunits in the hippocampus compared to group-housed rats (Serra et al., [@B174]), and greater enhancement of tonic current by gaboxadol (Sanna et al., [@B169]). Furthermore, δ subunit mRNA expression and protein was attenuated by ethanol consumption in socially isolated mice, in which basal expression was 50% greater than group-housed mice (Sanna et al., [@B169]). Whereas social isolation resulted in approximately 10% greater α~4~ subunit protein compared to group-housed mice drinking water, this difference was absent when the mice drank ethanol, suggesting that ethanol consumption opposed the effects of stress on α~4~ subunit expression and peptide up-regulation (Sanna et al., [@B169]). Ethanol consumption in socially isolated mice also resulted in electrophysiological effects of gaboxadol more similar to group-housed mice, consistent with regulation of α~4~δ subunits. Additional research is needed, as the combination of chronic ethanol and associated social stress in humans could have unique pharmacological consequences that are significant for the treatment of alcoholism.

Changes in GABA~A~ receptor subunit expression in relation to ethanol consumption have been studied using a primate model. By using non-human primates, chronic alcohol intake can be characterized in the absence of confounding variables present in human post-mortem studies (e.g., reliable measures of intake, multi-drug histories, nutrition). Studies using monkeys model important aspects of human alcohol consumption, including alcoholic-like patterns of intake with high (\>100 mg/dl) BECs (Grant et al., [@B73]). After more than 18 months of ethanol self-administration, previous studies found marked alterations in GABA~A~ and NMDA receptor subunit mRNA expression in the dorsal lateral prefrontal cortex (DLPFC) and the orbital frontal (OFC) but not in anterior cingulate cortex (ACC; Hemby et al., [@B86]; Acosta et al., [@B1]). Specifically, the GABA~A~ receptor subunits α~2~, α~4~, β~1~, β~3~, γ~1~, γ~2~, γ~3~, were decreased in the OFC, whereas only α~1~, α~2~, γ~1~, and δ were decreased in the DLPFC. These data suggest that GABA~A~ receptor adaptation in response to chronic ethanol drinking differed between cortical regions of the primate brain, and only the DLPFC showed changes in the δ subunit. Likewise, the only change observed with respect to α subunits was lowered expression, including a decrease in the α~4~ subtype within the OFC. The significance of these findings with regard to ethanol and neuroactive steroid pharmacology and effects on the HPA axis requires further investigation. However, Porcu et al. ([@B151]) found that the synthetic glucocorticoid dexamethasone suppressed plasma concentrations of deoxycorticosterone, and that the efficacy of dexamethasone was negatively correlated with subsequent ethanol self-administration using the primate model. Thus, lower glucocorticoid modulation of neuroactive steroid precursors may be a risk factor for heavy drinking, particularly among individuals with GABA~A~ receptor subunit polymorphisms associated with greater ethanol-like effects of neuroactive steroids (Pierucci-Lagha et al., [@B147]).

Inhibition of the HPA axis by GABAergic transmission is difficult to reconcile with the ability of ethanol, a positive modulator of GABA~A~ receptors, to activate the HPA axis and increase neuroactive steroids in rodents. One possibility is that activation of the sympathetic nervous system related to ethanol administration (restraint, needle poke) interacts with the effects of ethanol to increase neuroactive steroids. Barbaccia et al. ([@B8]) reported that CO~2~ inhalation increased neuroactive steroid precursors (pregnenolone, progesterone) in rat brain, but that the magnitude of increase was reduced after experience with handling, the experimental context, and the containment apparatus, twice daily for 5 days. A majority of studies using rats currently include 1--2 weeks of acclimation to the housing conditions, but few include daily handling. We measured plasma pregnenolone, progesterone, ACTH, and deoxycorticosterone in female rats that were extremely acclimated to the procedures and found no difference between rats administered 1.0 g/kg ethanol or water (i.g.; Helms et al., [@B83]). These rats had \>1 year daily handling and were gavaged 5--7 days/week in which 1.0 g/kg ethanol was administered on about half the days. Another explanation was recently suggested by Boyd et al. ([@B19]). Compared to rats fed an isocaloric control diet, rats fed an ethanol liquid diet for 7 days (8--10 g/kg/day) showed blunted plasma ACTH, progesterone, and allopregnanolone when injected with 2.0 g/kg ethanol. These data suggest tolerance develops to ethanol induction of neuroactive steroids. However, because administering ACTH restored the efficacy of ethanol to increase neuroactive steroids, adrenal responsiveness was not impaired by chronic ethanol. Instead, chronic exposure to ethanol also may alter steroidogenesis. For example, injection of pregnenolone (50 mg/kg, i.p.) increased allopregnanolone in the cortex of alcohol-preferring P rats, but only if they had been trained to self-administer ethanol (Besheer et al., [@B11]).

The Role of Endogenous Neuroactive Steroids in Sex Differences in the Effects of Ethanol
========================================================================================

Greater alcoholism risk among males is a robust observation in humans (Chan et al., [@B32]; Grant et al., [@B69]) and non-human primates (Vivian et al., [@B198]), suggesting that this sex difference is caused directly, at least in part, by biological rather social and behavioral differences. This sex difference is opposite in adult rodents and has been related to gonadal hormones (Vetter-O'Hagen et al., [@B197]; Vetter-O'Hagen and Spear, [@B196]), as testosterone appears to protect adult male rodents against heavy ethanol intake. Although contradictory results have been obtained in studies of both species, the results of human studies generally contrast with rodent findings to suggest that testosterone is a risk factor for heavy ethanol drinking. Testosterone is particularly important in the development of male-specific maturation in rodents and primates (Gupta et al., [@B76]; Sato et al., [@B170]). Although present in adult females, the concentration of circulating testosterone is much greater in adult male rodents (e.g., Pluchino et al., [@B150]) and primates (e.g., Muller et al., [@B134]), in whom it is linked to aggressive and reproductive behavior (Sato et al., [@B170]). Stålenheim et al. ([@B188]) reported that testosterone was associated with aggressive and antisocial behavior, which were more prevalent in alcoholic men with a family history of alcoholism. Among adolescent males, individuals with ≥3 symptoms of alcohol abuse had greater testosterone (*n* = 13, 0.16 nmol/l) than individuals with ≤2 symptoms (*n* = 451, 0.11 nmol/l). A significant positive correlation was found between total alcohol abuse symptoms and testosterone after adjusting for pubertal development (Eriksson et al., [@B51]). In another study using premenopausal females, testosterone was elevated among individuals with early onset alcohol abuse compared to controls, in contrast to decreased estradiol, progesterone, androstenedione, and sex hormone binding globulin (Pettersson et al., [@B145]). Consistent with a positive correlation between alcohol drinking and circulating androgens, a more recent study of post-menopausal women reported a significant association between testosterone and alcohol intake, which had a narrow range around 1.5 drinks per day (Wayne et al., [@B203]). In contradiction, however, Onland-Moret et al. ([@B139]) reported that testosterone concentrations were similar amongst post-menopausal women who drank \>2.5 drinks per day and those who abstained, although the androgen DHEA sulfate was elevated amongst the drinkers. In another correlative study, alcohol-preferring rats had greater baseline testosterone compared to alcohol non-preferring rats (Apter and Eriksson, [@B4]), which is inconsistent with the idea that testosterone protects against heavy alcohol drinking in male rodents. Few studies have tested the hypothesis that testosterone is causally related to ethanol drinking, and these have produced contradictory findings. First, among castrated male albino rats, those treated with testosterone more rapidly acquired a greater preference for ethanol compared to those treated with estradiol, progesterone, or oil control solution (Lakoza and Barkov, [@B113]). On the other hand, castrated male Sprague-Dawley rats showed greater ethanol intake (2.2 g/kg/2 h) compared to sham rats (1.4 g/kg/2 h), which was decreased on average by testosterone replacement (1.75 g/kg/2 h; Vetter-O'Hagen et al., [@B195]). Many procedural differences could account for these discrepant findings, including "alcoholization" by Lakoza and Barkov ([@B113]) in which ethanol was administered intraperitoneally for 2 weeks prior to access to ethanol, and the use of a sweetened solution by Vetter-O'Hagen et al. ([@B195]). Overall, a majority of studies suggest that testosterone influences the risk for heavy drinking, although obviously more work is needed to determine a causal mechanism. In terms of neurosteroids, one possible mechanism is metabolism to androsterone.

Androsterone, as reviewed above, has discriminative stimulus effects similar to ethanol (monkeys, Grant et al., [@B72]) and pregnanolone (rats, Engel et al., [@B50]), and therefore could increase sensitivity to ethanol via additive pharmacological effects. Consistent with the distinct pharmacological effects of isomers of neuroactive steroids, 3α,5α-androsterone, but not 3β,5α-androsterone, is a low-potency but efficacious anticonvulsant (Kaminski et al., [@B101]). In one study, male volunteers, who may have been social drinkers, had high levels of circulating androsterone in the form of a glucuronide or sulfated conjugate (androsterone glucuronide, 45 ng/ml; Hsing et al., [@B97]), compared to 97 pg/ml for the non-conjugated form of androsterone (Porcu et al., [@B152]). Fabre et al. ([@B52]) reported that both androsterone isomers (3α,5α- and 3α,5β-androsterone) were present in lower concentrations among actively drinking (mean BEC, 148 mg/dl; 5α, 0.43 mg/24 h; 5β, 0.29 mg/14 h) compared to abstinent alcoholics (5α, 0.95 mg/24 h; 5β, 0.71 mg/24 h) or controls (5α, 1.4 mg/24 h; 5β, 0.63 mg/24 h). To our knowledge, glucuronide or sulfate conjugates of androgens have not been measured in heavy drinkers. If the older results of Fabre et al. ([@B52]) are confirmed, lower levels of androgens in alcoholics could indicate that the role of androgens in alcoholism is primarily as a risk factor and not a regulator of ethanol sensitivity or consummatory behavior, although once again, only correlative data is available.

Although present in males, progesterone concentration is two-fold greater in reproductively fertile women (Genazzani et al., [@B61]). Progesterone mediates reproductive behavior related to pregnancy that supports fetal development such as increased consummatory behavior (hyperphagia, Douglas et al., [@B47]). Females of old-world primates (including humans) have menstrual cycles that occur over approximately 28--30 days. Following a 10- to 12-day follicular phase, a rapid rise in luteinizing hormone and estrogen precedes ovulation at mid-cycle (Hotchkiss and Knobil, [@B96]). In contrast, rodents have a 4-day estrus cycle during which rising estradiol precedes a surge of luteinizing hormone that coincides with the onset of proestrus and induces ovulation. Rodent ovaries produce progesterone and progesterone-derived neuroactive steroids (Holzbauer, [@B93]) such that circulating levels rise throughout proestrus. Approximately 12 h after the luteinizing hormone surge, ovulation coincides with peak progesterone which declines throughout estrus (Goldman et al., [@B66]). In primates, progesterone mediates development of the uterine epithelium prior to menses, but in rodents, progesterone mediates the cellular composition of the vaginal epithelium.

The duration of exposure to endogenous neuroactive steroids across the menstrual or estrus cycle may influence subsequent effects of ethanol. For example, declining progesterone in the latter half of the primate luteal phase after prolonged (about 1 week) progesterone exposure could enhance the aversive effects of ethanol withdrawal. Compared to vehicle, twice daily injection of progesterone (5 mg/kg) to rats maintained on a chronic ethanol diet increased anxiety during ethanol withdrawal measured using elevated plus maze (Sharma et al., [@B180]). Exposure to progesterone for several days altered the pharmacological activity of allopregnanolone, and GABA~A~ receptor subunit expression (i.e., increased α~4~ and δ, decreased α~1~ subunits; reviewed by Smith et al., [@B187]; Maguire and Mody, [@B124]). Indeed, tolerance to endogenous neuroactive steroids during the menstrual cycle and during pregnancy correlated with changes in GABA~A~ receptor subunit conformation and function (Turkmen et al., [@B192]). Differences between rodents and primates in the time-course of endogenous progesterone concentration during reproductive cycles suggests that primate studies will provide important translational data about the influence of fluctuations in endogenous neuroactive steroids on sensitivity to ethanol, including withdrawal from chronic ethanol.

Consistent with sex differences in ethanol drinking and alcoholism susceptibility, males and females differ in symptoms of ethanol withdrawal (reviewed by Finn et al., [@B56]). For example, compared to males, female rats are susceptible to seizures for fewer days after ethanol withdrawal (Alele and Devaud, [@B2]). Furthermore, withdrawal symptoms are ameliorated by GABAergic neurosteroids differentially in male and female rodents (e.g., Devaud et al., [@B44]). In one study, rats' amplitude of startle to an auditory stimulus was slightly enhanced during withdrawal from ethanol compared to withdrawal from a dextrose diet, but only in male rats, not sham or ovariectomized female rats. This effect was attenuated by progesterone (Reilly et al., [@B160]). In female mice, the magnitude of handling-induced convulsions during ethanol withdrawal was increased by finasteride, suggesting modulation by 5α-reduced neuroactive steroids. In contrast, finasteride decreased the magnitude of handling-induced convulsions in males (Gorin-Meyer et al., [@B67]). Sex differences in anticonvulsant effects of endogenous neurosteroids could relate to basal steroid concentrations. In male mice, removal of endogenous neurosteroids by adrenalectomy increased seizure magnitude during acute ethanol withdrawal, with no additional effect of gonadectomy. In contrast, in female mice, both adrenalectomy and gonadectomy were necessary to potentiate handling-induced convulsions during ethanol withdrawal. In both sexes, treatment with progesterone or deoxycorticosterone decreased the severity of convulsions (Kaufman et al., [@B103]). The absence of an effect of gonadectomy in males suggests that testosterone and its neuroactive metabolites have little impact on seizure susceptibility during ethanol withdrawal (Finn et al., [@B56]), or perhaps *de novo* testosterone synthesis in the brain could be up-regulated to compensate for gonadectomy.

Withdrawal seizures in alcoholics have a relatively low incidence, even among humans undergoing alcoholism treatment (8--16%; Caetano et al., [@B26]). A more commonly reported withdrawal syndrome is anxiety, often comorbid with alcohol dependence in humans (Kushner et al., [@B112]). Repeated high doses of ethanol followed by withdrawal from ethanol decrease the threshold for seizures similar to kindling, in which seizure threshold is reduced by repeated sub-threshold electrical activity (reviewed by Breese et al., [@B22]; Rogawski, [@B163]). Kia et al. ([@B109]) reported that daily electrical stimulation of the basolateral amygdala, which elicited convulsions, also eliminated the potentiation of tonic currents by THDOC in pyramidal neurons of the piriform cortex. Thus, kindling resulting in basal neural excitation was associated with decreased efficacy of a neuroactive steroid to enhance tonic currents. These *in vitro* data are reminiscent of the reports of cross-tolerance to alphaxalone-induced sleep after CIE, which includes daily withdrawal (Cagetti et al., [@B27]). Basal neurosteroid concentrations may regulate seizure threshold via modulation of tonic currents, and changes in neurosteroid concentrations in alcoholics that undergo abstinence could represent attempts to maintain homeostasis of neural excitability.

Ethanol and Neuroactive Steroid Effects in Relation to Changes in GABA Neurotransmission during Maturation
==========================================================================================================

The expression of GABA~A~ receptor subunits is developmentally regulated. However, the effect of ethanol and neuroactive steroids on different components of GABA neurotransmission has rarely been investigated at different maturational stages. In the cerebellum and thalamus of rodents, the δ subunit and associated α subunits (α~4~/α~6~) are not expressed at birth (developmentally equivalent to humans in the third trimester of pregnancy), but they are progressively expressed over the first month of life (roughly peaking at puberty). Accordingly, in those brain regions, tonic GABA~A~ currents, mediated by α~4~/α~6~δ containing GABA~A~ receptors, first appear at \~15 days, and get progressively larger until adulthood (Brickley et al., [@B23]; Wall and Usowicz, [@B199]; Peden et al., [@B144]). In contrast, tonic GABA~A~ currents mediated by α~4~δ subunits are present at birth in the hippocampus (Holter et al., [@B92]). Thus, the role of extrasynaptic GABA~A~ receptors and tonic inhibition in mediating neurosteroid and ethanol actions may be broadly developmentally regulated in some brain regions (cerebellum/thalamus) but not in others (hippocampus). In addition to developmental changes in GABA~A~ receptors, there are developmental changes in the transporters that establish the Cl^−^ gradient which is what makes GABA~A~ receptors inhibitory in the adult (Wang and Kriegstein, [@B201]). Accordingly, in the early post-natal period in rodents (third trimester in humans) GABA~A~ receptors are excitatory and play a crucial role in maturation of the nervous system (Eilers et al., [@B49]; Wang and Kriegstein, [@B201]). Thus, neurosteroid and ethanol enhancement of GABA~A~ receptors in the human fetus is likely to be excitatory, and may interfere with proper brain development. In the case of ethanol, such interference may contribute to the brain damage underlying fetal alcohol syndrome (Costa et al., [@B36]; Galindo et al., [@B59]).

As well as the broad developmental changes in the GABAergic system that likely affect the impact of neurosteroids and ethanol, there are specific developmental changes in the GABAergic system that may influence responses to neurosteroids and ethanol. Specifically, GABA neurotransmission appears to be distinct during puberty (post-natal days 35--45 in mice), which may contribute to the vulnerability of adolescents to alcohol abuse and dependence (Grant and Dawson, [@B68]). Shen et al. ([@B183]) reported 300 and 700% greater α~4~ and δ subunit expression, respectively, on dendritic spine (not shaft) membranes of CA1 pyramidal cells in pubertal compared to pre-pubertal and adult female mice. Additionally, whereas allopregnanolone potentiated GABA-induced currents and decreased anxiety in adult rodents (Finn and Purdy, [@B58]), allopregnanolone increased anxiety and decreased tonic GABA-induced currents (CA1 pyramidal cells) in female mice during puberty. This differential effect of allopregnanolone was related to a basal outward Cl^−^ current at α~4~βδ receptors during puberty, as opposed to inward during adulthood (Shen et al., [@B182]). Pyramidal cells of pubertal mice were more sensitive to currents induced by the α~4~ and δ subunit-selective agonist gaboxadol, consistent with the unique subunit expression occurring during puberty. Allopregnanolone (30 nM) facilitated long-term potentiation and spatial learning in pubertal mice, but decreased long-term potentiation in pre-pubertal mice (Shen et al., [@B183]). A pattern of ethanol exposure in rats meant to model binge drinking in adolescence (3 g/kg/day, 8 days of injections with two intervening saline injections) heightened HPA axis reactivity to stress (acute ethanol) as adults (Przybycien-Szymanska et al., [@B155]). Ethanol exposure during the sensitive pubertal period could disrupt the maturation of stress response systems including neurosteroid regulation of homeostasis, perhaps altering ethanol sensitivity, and increasing risk of alcoholism.

Future Directions
=================

An area of research needing attention is the contribution of neurosteroids to ethanol effects on sleep, an essential process regulating mood and responses to stress that is disrupted in alcoholism (Brower, [@B24]). A key brain structure involved in sleep is the ventrolateral preoptic area of the hypothalamus, which sends galanin and GABA projections to brainstem arousal nuclei to maintain sleep, with reverse inhibitory projections maintaining wakefulness (Harrison, [@B81]). During the first half of a sleep bout, high doses of ethanol decrease the latency to sleep onset, increase slow-wave sleep and decrease rapid eye movement (REM) sleep (young adult women; Williams et al., [@B206]), whereas the opposite effects are observed in the last half of a sleep bout (Feige et al., [@B55]). Sleep deprivation interacts with ethanol to potentiate daytime sleepiness and performance impairments due to ethanol (Roehrs and Roth, [@B162]). Both alcoholic men and women were reported to have more REM sleep, and less slow-wave sleep, compared to controls, with altered electroencephalograms during non-REM sleep (Gann et al., [@B60]; Colrain et al., [@B35]). A recent study found that moderately intoxicating doses of ethanol are associated with greater sleep disruption in women compared to men (Arnedt et al., [@B5]). It is tempting to speculate that neuroactive steroids could be a factor in sex differences in ethanol-induced disruption of sleep. Only a few studies, however, have investigated neuroactive steroid influences on sleep. Pregnenolone sulfate (47.5 mg/kg) increased REM sleep in rats without affecting slow-wave sleep or wakefulness (Darnaudéry et al., [@B43]). Administration of 15 mg/kg allopregnanolone per day for 5 days to rats dramatically altered the timing of sleep stages including decreased non-REM episodes, decreased latency to non-REM sleep, and increased latency to REM sleep (Damianisch et al., [@B39]). The effects of acute allopregnanolone and THDOC are similar, both decreasing sleep latency and increasing the duration of transition between non-REM and REM sleep (Müller-Preuss et al., [@B135]). Likewise, allopregnanolone (7.5 and 15 mg/kg) decreased the latency to sleep and increased the time in transition between non-REM and REM sleep (rats, Lancel et al., [@B114]). Pregnenolone sulfate regulated the percentage of REM sleep, but not non-REM or wakefulness, when infused into the pedunculopontine tegmentum, a component of the reticular formation (Darbra et al., [@B40]). In contrast, up to 100 mg/kg dehydroepiandrosterone sulfate does not affect sleep cycles, but affects electroencephalograms associated with non-REM sleep (Schiffelholz et al., [@B173]). Additional studies are needed to determine whether neurosteroid mechanisms are involved in ethanol influences on sleep, and whether neuroactive steroids could ameliorate sleep deficits in alcoholics.

Summary
=======

Investigation of the effects of neuroactive steroids has come a long way since the first realizations of their shared receptor mechanisms with ethanol. These common receptor mechanisms (e.g., GABA~A~, NMDA receptors) mediate neurotransmission in ubiquitous neural pathways regulating excitation and inhibition across many brain areas. The diversity of neuronal types regulated by GABA and glutamate and expressing receptors for these neurotransmitters accounts for the multiple behavioral effects of ethanol and their modulation by neuroactive steroids. Neuroactive steroids appear to be able to modify many of the behaviors affected by ethanol along a continuum broadly bounded by excitation (anxiety or vigilance, convulsions, perhaps impulsivity) and inhibition (anxiolysis, decreased seizure threshold, sedation, ataxia). The endogenous role of neuroactive steroids in regulating these behaviors provides a window into the abnormalities observed in alcoholics. The strongest candidates for the endogenous ligands acting at the receptor systems mediating ethanol effects are neuroactive steroids, although not all of the receptor systems were covered in this review (e.g., 5-hydroxytryptamine receptors, sigma receptors). Additional evidence for neuroactive steroids as endogenous alcohols comes from their common metabolic substrates (Figure [1](#F1){ref-type="fig"}). Although we have learned much, it has only been less than 30 years since Harrison and Simmond's ([@B82]) study of the anesthetic actions of alphaxalone, and plenty of work remains to be done. For example, clarifying the functions of neuroactive steroids in maturation is likely to reveal the mechanisms for abnormalities induced by prenatal alcohol. It has been 20 years since the initial studies linking neuroactive steroids to the HPA axis (e.g., Purdy et al., [@B157]). The HPA axis may serve as a bridge between peripheral organs, the brain, and ultimately behavior to for optimal energy utilization depending on environmental conditions. Neuroactive steroids may be a central mechanism by which these environmental conditions are signaled to the brain, HPA axis, and the rest of the body. The significance of neuroactive steroids for a variety of physiological and behavioral processes affected by ethanol suggests that they should continue to be a focus of research for alcoholism therapies.
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